Expertise in
14
conditions

Dr. Vijay K. Gunuganti

Oncology
Cancer Care Network Of South Texas PA
18707 Hardy Oak Blvd Ste 320, 
San Antonio, TX 
Accepting New Patients
Offers Telehealth
Expertise in
14
conditions
Cancer Care Network Of South Texas PA
18707 Hardy Oak Blvd Ste 320, 
San Antonio, TX 

Overview

Vijay Gunuganti is an Oncologist practicing medicine in San Antonio, Texas.

Dr. Gunuganti is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Myelodysplastic Syndrome (MDS), Lung Cancer, and Renal Cell Carcinoma (RCC).

He is actively involved in clinical research, co-authoring 4 peer reviewed articles and participating in 3 clinical trials. Dr. Gunuganti is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in TX

Hospital Affiliations

Baptist Medical Center
Methodist Hospital Stone Oak
Methodist Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
Community First Health Plans
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
EMI Health
  • PPO
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Netcare Life And Health Insurance
  • OTHER COMMERCIAL
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 16 Less Insurance Carriers -

Locations

Cancer Care Network of South Texas PA
18707 Hardy Oak Blvd Ste 320, San Antonio, TX 78258
Other Locations
Cancer Care Network of South Texas PA
2130 NE Loop 410 Ste 100, San Antonio, TX 78217

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum -Based Chemotherapy With Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum -Based Chemotherapy With Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)
Enrollment Status: Completed
Publish Date: June 18, 2026
Intervention Type: Biological, Drug
Study Drugs: Niraparib, Pembrolizumab
Study Phase: Phase 3
A Phase 1b, Open-Label, Dose-Escalation, Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors
A Phase 1b, Open-Label, Dose-Escalation, Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: August 09, 2024
Intervention Type: Drug
Study Drugs: SM08502, Abiraterone, Prednisone, Docetaxel, FOLFIRI Protocol, Panitumumab
Study Phase: Phase 1
A Randomized, Double Blind, Multicenter, Parallel-group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men With Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy
A Randomized, Double Blind, Multicenter, Parallel-group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men With Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy
Enrollment Status: Completed
Publish Date: April 06, 2021
Intervention Type: Biological
Study Phase: Phase 3
View 2 Less Clinical Trials

4 Total Publications

Lurbinectedin in treating CNS metastases from small cell neuroendocrine prostate cancer-a case report.
Lurbinectedin in treating CNS metastases from small cell neuroendocrine prostate cancer-a case report.
Journal: Frontiers in oncology
Published: March 27, 2026
Similar Doctors
Expertise in
17
conditions
Expertise in
17
conditions
Referral may be required

University Of Texas Health Science Center At San Antonio

7979 Wurzbach Rd, 
San Antonio, TX 
 (9.7 miles away)
210-450-1000
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Andrew Brenner is an Oncologist practicing medicine in San Antonio, Texas. Dr. Brenner is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Astrocytoma, Glioblastoma, Glioma, Colonoscopy, and Endoscopy. Dr. Brenner is currently accepting new patients.

Expertise in
25
conditions
Expertise in
25
conditions
Referral may be required

University Of Texas Health Science Center At San Antonio

7979 Wurzbach Rd, 
San Antonio, TX 
 (9.7 miles away)
210-450-1143
Languages Spoken:
English, Mandarin
See accepted insurances
Accepting New Patients
Offers Telehealth

Lei Zheng is an Oncologist practicing medicine in San Antonio, Texas. Dr. Zheng is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Familial Pancreatic Cancer, Pancreaticoduodenectomy, and Hepato-Pancreato-Biliary Surgery. Dr. Zheng is currently accepting new patients.

Expertise in
18
conditions
Expertise in
18
conditions
Referral may be required

Texas Oncology - San Antonio Medical Center

5206 Research Dr, 
San Antonio, TX 
 (10.0 miles away)
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Antonio Santillan-Gomez is an Oncologist practicing medicine in San Antonio, Texas. Dr. Santillan-Gomez is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Ovarian Carcinosarcoma, Virilizing Ovarian Tumor, Cervical Cancer, Salpingo-Oophorectomy, and Hernia Surgery. Dr. Santillan-Gomez is currently accepting new patients.

Frequently Asked Questions about Dr. Vijay K. Gunuganti

How do I make an appointment with Dr. Vijay K. Gunuganti?

You can book an appointment with Dr. Vijay K. Gunuganti by calling their office at 210-545-6972. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Vijay K. Gunuganti a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Vijay K. Gunuganti is classified as an Advanced expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Vijay K. Gunuganti specialize in?

While Dr. Vijay K. Gunuganti is a Oncology, they have specific expertise in Multiple Myeloma, Myelodysplastic Syndrome (MDS), and Lung Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Vijay K. Gunuganti participate in research or clinical trials?

Yes. Dr. Vijay K. Gunuganti has published 4 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Dr. Vijay K. Gunuganti's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Vijay K. Gunuganti accept my insurance?

Dr. Vijay K. Gunuganti accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 210-545-6972 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gunuganti's expertise for a condition
ConditionClose
      View All 14 Advanced Conditions
      View All 71 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile